查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611366

思觉失调症治疗药物市场：按治疗层级、剂量方法和分销管道 - 全球预测 2025-2030

Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年思觉失调症治疗药物市场价值为78.9亿美元，预计到2024年将达到80.8亿美元，复合年增长率为4.94%，到2030年将达到110.6亿美元。

思觉失调症药物市场包括多种治疗方法，包括抗精神病药物、心理治疗和旨在控制思觉失调症症状（如妄想、幻觉和认知障碍）的生活方式调整。思觉失调症是一种慢性且严重的疾病，通常始于青春期晚期和成年早期，需要长期治疗策略来改善患者的生活品质。应用范围涵盖医院、诊所和復健中心，影响患者、看护者和医疗保健提供者等最终用户。成长要素包括诊断率的提高、新药和治疗方法研究的增加以及公众心理健康意识的提高。精神疾病盛行率的上升，加上对精神疾病去人格化的持续努力，可能会推动市场扩张。为抗治疗性患者开发标靶治疗方法以及整合人工智慧主导的诊断和监测系统等数位技术，可以个人化和优化治疗方法，正在开闢新的机会。然而，该市场受到多种挑战的限制，包括开发新治疗方法的高成本、现有药物的副作用以及某些地区获得精神卫生保健的机会有限。此外，与精神疾病相关的耻辱也是阻碍患者治疗性介入的因素。从创新的角度来看，潜在的机会包括开发副作用较少的下一代抗精神病药物、基因组学的进步以提供客製化治疗，以及使用行动医疗应用程式来追踪治疗依从性和患者进展，这被认为是一个重大成长。此外，製药公司、科技公司和医疗保健提供者之间的相互合作可以促进进步并消除市场障碍。持续的市场研究和应对监管变化对于在这个充满活力的重要行业中获得市场占有率和实现持续增长至关重要。

主要市场统计
基准年[2023] 78.9亿美元
预计年份 [2024] 80.8亿美元
预测年份 [2030] 110.6亿美元
复合年增长率（%） 4.94%

市场动态：快速发展的思觉失调症药物市场的关键市场洞察

供需的动态交互作用正在改变思觉失调症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球思觉失调症患者数量增加
    • 政府提高对精神疾病认知的措施和宣传活动
    • 持续研究开发高效思觉失调症治疗药物
  • 市场限制因素
    • 治疗费用上涨且缺乏保险覆盖
  • 市场机会
    • 日益关注个人化医疗以提高思觉失调症患者的药物疗效
    • 思觉失调症的治疗方法进展
  • 市场挑战
    • 与思觉失调症药物相关的副作用

波特的五力：驾驭思觉失调症药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对思觉失调症药物市场的影响

外部宏观环境因素在塑造思觉失调症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解思觉失调症治疗药物市场的竞争状况

对思觉失调症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV思觉失调症药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估思觉失调症治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划思觉失调症治疗药物市场的成功之路

思觉失调症治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地思觉失调症的发生率正在上升
      • 政府提高人们对精神健康障碍意识的措施和宣传活动
      • 持续研究发展思觉失调症的有效治疗方法
    • 抑制因素
      • 治疗费用上涨和保险覆盖率低
    • 机会
      • 更重视个人化医疗以提高思觉失调症患者的药物疗效
      • 思觉失调症的治疗和治疗方法进展
    • 任务
      • 与思觉失调症药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级的思觉失调症治疗药物市场

  • 第二代
  • 第三代

第七章思觉失调症治疗药物市场管理按市场管理

  • 可注射的
  • 口服

第八章思觉失调症管道

  • 医院
  • 药局
    • 离线
    • 在线的

第九章 北美和南美思觉失调症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区思觉失调症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的思觉失调症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc by AbbVie Inc.
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb and Company
  • Delpor, Inc.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • Johnson & Johnson Services, Inc.
  • Karuna Therapeutics Inc
  • Lundbeck A/S
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka America Pharmaceutical Inc.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market was valued at USD 7.89 billion in 2023, expected to reach USD 8.08 billion in 2024, and is projected to grow at a CAGR of 4.94%, to USD 11.06 billion by 2030.

The schizophrenia therapeutics market encompasses a wide range of treatments including antipsychotic medications, psychotherapy, and lifestyle adjustments aimed at managing schizophrenia symptoms - such as delusions, hallucinations, and cognitive difficulties. Necessity arises from the chronic and severe nature of the disorder, typically emerging in late adolescence or early adulthood, thereby demanding long-term treatment strategies to improve patient quality of life. Applications span across hospitals, clinics, and rehabilitation centers, impacting end-users such as patients, caregivers, and healthcare providers. Growth factors include increased diagnosis rates, enhanced research into novel medications and treatment methodologies, and a greater public awareness about mental health. The rising prevalence of mental health disorders coupled with ongoing efforts to destigmatize mental illness can foster market expansion. Emerging opportunities are prevalent in developing therapies targeting treatment-resistant patients and the integration of digital technologies, like AI-driven diagnostics and monitoring systems, that can personalize and optimize treatment regimens. However, the market is constrained by several challenges, including high development costs for new therapies, side effects associated with existing medications, and limited access to mental health care in certain regions. Stigma still attached to mental illnesses can also hinder patient engagement in therapeutic interventions. From an innovation standpoint, potential growth areas include the development of next-generation antipsychotics with fewer side effects, advancements in genomics to offer tailored therapies, and leveraging mobile health applications to track treatment adherence and patient progress. Furthermore, cross-collaboration between pharmaceutical companies, technology firms, and healthcare providers can spur advancement and break market barriers. Continuous market research and adaptation to regulatory changes are essential for capturing market share and driving sustainable growth in this dynamic and vital sector.

KEY MARKET STATISTICS
Base Year [2023] USD 7.89 billion
Estimated Year [2024] USD 8.08 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 4.94%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Schizophrenia Therapeutics Market

The Schizophrenia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of schizophrenia disorder among individuals worldwide
    • Government initiatives and campaigns to raise awareness regarding mental health conditions
    • Ongoing research for the development of efficient drugs for schizophrenia
  • Market Restraints
    • High cost of treatment and lack of insurance coverage
  • Market Opportunities
    • Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
    • Advancements in schizophrenia treatment and therapeutics
  • Market Challenges
    • Side effects associated with the medications prescribed for schizophrenia

Porter's Five Forces: A Strategic Tool for Navigating the Schizophrenia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Schizophrenia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Schizophrenia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Schizophrenia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Schizophrenia Therapeutics Market

A detailed market share analysis in the Schizophrenia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Schizophrenia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Schizophrenia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Schizophrenia Therapeutics Market

A strategic analysis of the Schizophrenia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Second Generation and Third Generation.
  • Based on Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital and Pharmacies. The Pharmacies is further studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
      • 5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
      • 5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
      • 5.1.3.2. Advancements in schizophrenia treatment and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Second Generation
  • 6.3. Third Generation

7. Schizophrenia Therapeutics Market, by Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Schizophrenia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Pharmacies
    • 8.3.1. Offline
    • 8.3.2. Online

9. Americas Schizophrenia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Schizophrenia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acadia Pharmaceuticals Inc.
  • 2. Alkermes Plc
  • 3. Allergan Plc by AbbVie Inc.
  • 4. Amneal Pharmaceuticals, LLC
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca plc
  • 7. BioXcel Therapeutics, Inc.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb and Company
  • 10. Delpor, Inc.
  • 11. Eli Lilly and Company
  • 12. Gedeon Richter Plc
  • 13. Johnson & Johnson Services, Inc.
  • 14. Karuna Therapeutics Inc
  • 15. Lundbeck A/S
  • 16. Luye Pharma Group Ltd
  • 17. Lyndra Therapeutics Inc
  • 18. Meiji Holdings Co., Ltd.
  • 19. Neurocrine Biosciences, Inc.
  • 20. Otsuka America Pharmaceutical Inc.
  • 21. Pfizer Inc.
  • 22. Reviva Pharmaceuticals Holdings, Inc.
  • 23. Sumitomo Dainippon Pharma Co., Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 187. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 188. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023